Tanabe Pharma Corp - Company Profile
Powered by 
All the sales intelligence you need on Tanabe Pharma Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Tanabe Pharma Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Tanabe Pharma Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Tanabe Pharma Corp (Tanabe), formerly Mitsubishi Tanabe Pharma Corp, a subsidiary of Mitsubishi Chemical Group Corp, specializes in the development, manufacture, and marketing of pharmaceutical products. The company offers an array of ethical drugs for the treatment of autoimmune diseases, diabetes, kidney diseases, central nervous system (CNS) disorders, and other conditions, as well as vaccines for infectious diseases. Its products are distributed through pharmaceutical wholesalers, hospitals, clinics, and drugstores.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Tanabe Pharma is actively advancing its research and development pipeline, focusing on innovative treatments across a range of therapeutic areas. The company’s pipeline includes several promising candidates, such as MT-5199 (Dysval/Valbenazine) for tardive dyskinesia and MT-210 (Roluperidone) for schizophrenia. It is also developing MT-3921 (Unasnemab) for spinal cord injury and HTLV-1-associated myelopathy, alongside MT-0551 (Uplizna/Inebilizumab) for myasthenia gravis and IgG4-related disease. Tanabe is addressing various CNS disorders with MT-0612 (Levodopa/Carbidopa) for Parkinson’s disease and MT-2111 (Loncastuximab tesirine) for relapsed/refractory diffuse large B-cell lymphoma. It is also working on MT-7117 (Dersimelagon) for erythropoietic protoporphyria and systemic sclerosis, as well as MT-2990 for ANCA-associated vasculitis. Additionally, MT-3534 targets autoimmune diseases, and MT-2765 focuses on hypertension. The company is advancing treatments for chronic kidney disease and type 2 diabetes mellitus with TA-7284 (Canaglu/INVOKANA) and MT-2412 (CANALIA), which combines Teneligliptin and Canagliflozin.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer